Kiadis Pharma N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
09 dec 2015 - 18:00
Statutaire naam
Kiadis Pharma N.V.
Titel
Kiadis Pharma announces results of extraordinary general meeting of shareholders
Bericht
Kiadis Pharma announces results of extraordinary general meeting of shareholders
Amsterdam, The Netherlands, December 9, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, announces that it held an extraordinary general meeting of shareholders today at the Amsterdam Stock Exchange (Euronext) in Amsterdam, The Netherlands. Shareholders approved the one resolution that was on the agenda, being the appointment of KPMG Accountants N.V. as Kiadis Pharma's external auditor for the financial year 2015.
About Kiadis Pharma
Kiadis Pharma is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The Company believes that its innovative products have the potential to address the current risks and limitations connected with allogeneic hematopoietic stem cell transplantation (HSCT), being graft-versus-host-disease (GVHD), cancer relapse, opportunistic infections and limited matched donor availability. HSCT is generally regarded as the most effective curative approach to blood cancers and certain inherited blood disorders and the Company expects that HSCT could become a first-choice treatment for blood cancers and inherited blood disorders once current risks and limitations are addressed, thereby meeting a significant unmet medical need with its products.
Currently, the Company’s product ATIR101™ is being tested using a single dose regimen in an open-label Phase II trial in patients with blood cancer who have not found a matching donor and where a partially matched (haploidentical) family member is used as donor for HSCT. Kiadis Pharma announced full enrolment of this trial in July 2015. The primary endpoint for the last p
Datum laatste update: 14 februari 2025